UBE2V1 anticorps (AA 113-145)

N° du produit ABIN3029435

Détail du produit anti-UBE2V1 anticorps

Antigène: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Épitope: AA 113-145

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp UBE2V1 est non-conjugé

Application: Western Blotting (WB), ELISA

Réactivité croisée (Details): Expected species reactivity: Rat, Bovine, Chicken, Zebrafish, Xenopus

Purification: Purified

Immunogène: A portion of amino acids 113-145 from the human protein was used as the immunogen for this UBE2V1 antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the UBE2V1 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS pH 7.4 with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the UBE2V1 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur UBE2V1

Antigène: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Autre désignation: UBE2V1 (UBE2V1 Produits)

Synonymes: anticorps CIR1, anticorps CROC-1, anticorps CROC1, anticorps UBE2V, anticorps UEV-1, anticorps UEV1, anticorps UEV1A, anticorps 0610011J09Rik, anticorps AI256840, anticorps D7Bwg1382e, anticorps CROC-1B, anticorps ubiquitin conjugating enzyme E2 V1, anticorps ubiquitin-conjugating enzyme E2 variant 1, anticorps UBE2V1, anticorps ube2v1, anticorps Ube2v1

Sujet: The CROC1 isoforms, also known as UBE2V1, show sequence similarity to ubiquitin-conjugating enzymes (UBCs, or E2s) but lack the conserved cysteine residue critical to catalytic activity of E2s.1 Northern blot analysis detected approximately 2.1- and 2.5-kb CROC1 transcripts in all human tissues examined, with the highest levels in brain, skeletal muscle, and kidney. Partial human intestinal epithelial cell cDNAs have been isolated containing the 3-primecoding sequence and 3-prime untranslated region of UBE2V1, also called UEV1.2 UEV1 does not have ubiquitin-conjugating activity in vitro. UEV1 transcripts are downregulated upon differentiation of a colon carcinoma cell line.1 Constitutive expression of exogenous UEV1 protein in these colon carcinoma cells inhibits their capacity to differentiate upon confluence and induces changes in cell cycle behavior associated with inhibition of CDK1. A heterodimeric protein complex has been identified that links TRAF6 to IKK activation.3 Peptide mass fingerprinting analysis revealed that this complex is composed of the ubiquitin conjugating enzyme UBC13 and the UBC-like protein UBE2V1, also called UEV1A. TRAF6, a RING domain protein, functions together with UBC13/UEV1A to catalyze the synthesis of unique polyubiquitin chains linked through lysine-63 (K63) of ubiquitin. Blockade of this polyubiquitin chain synthesis, but not inhibition of the proteasome, prevents the activation of IKK by TRAF6. These results unveil a new regulatory function for ubiquitin, in which IKK is activated through the assembly of K63-linked polyubiquitin chains.

UniProt: Q13404

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Toll-Like Receptors Cascades